Applied Therapeutics Inc. (APLT)
NASDAQ: APLT
· Real-Time Price · USD
0.47
0.06 (13.36%)
At close: May 02, 2025, 3:59 PM
0.46
-0.82%
After-hours: May 02, 2025, 05:46 PM EDT
13.36% (1D)
| Bid | 0.46 |
| Market Cap | 65.96M |
| Revenue (ttm) | 456K |
| Net Income (ttm) | -105.62M |
| EPS (ttm) | -0.76 |
| PE Ratio (ttm) | -0.61 |
| Forward PE | -0.93 |
| Analyst | Hold |
| Ask | 0.49 |
| Volume | 3,654,389 |
| Avg. Volume (20D) | 2,265,274 |
| Open | 0.42 |
| Previous Close | 0.41 |
| Day's Range | 0.40 - 0.49 |
| 52-Week Range | 0.29 - 10.62 |
| Beta | 1.89 |
About APLT
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the...
Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2019
Employees 35
Stock Exchange NASDAQ
Ticker Symbol APLT
Analyst Forecast
According to 6 analyst ratings, the average rating for APLT stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 973.19% from the latest price.
Stock ForecastsNext Earnings Release
Applied Therapeutics Inc. is scheduled to release its earnings on May 16, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-13.72%
Applied Therapeutics shares are trading lower afte...
Unlock content with
Pro Subscription
5 months ago
-13.79%
Applied Therapeutics shares are trading lower after UBS downgraded the stock from Buy to Neutral and cut its price target from $13 to $2.
